Where BioXcel Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 10 analysts have published their opinion on BioXcel Therapeutics (NASDAQ:BTAI) stock. The average price target is $19.6, implying an upside from the current price of $3.45. This represents a 63.7% decrease from the previous average price target of $54.00. The majority of the ratings are bullish.
September 08, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have given a bullish outlook on BioXcel Therapeutics with an average price target of $19.6, indicating potential upside from the current price.
The bullish outlook from analysts indicates a positive sentiment towards BioXcel Therapeutics. The average price target of $19.6 is significantly higher than the current price of $3.45, suggesting potential upside. However, this is a decrease from the previous average price target of $54.00, indicating a potential shift in sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100